EYENOVIA INC (EYEN) Stock Fundamental Analysis
NASDAQ:EYEN - Nasdaq - US30234E2037 - Common Stock - Currency: USD
EYEN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EYEN have multiple concerns. EYEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
EYEN had negative earnings in the past year.
EYEN had a negative operating cash flow in the past year.
EYEN had negative earnings in each of the past 5 years.
EYEN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -708.22%, EYEN is not doing good in the industry: 96.91% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -708.22% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for EYEN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EYEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
EYEN has more shares outstanding than it did 1 year ago.
EYEN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for EYEN is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -62.11, we must say that EYEN is in the distress zone and has some risk of bankruptcy.
EYEN has a Altman-Z score of -62.11. This is amonst the worse of the industry: EYEN underperforms 93.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -62.11 |
ROIC/WACCN/A
WACC10.96%
2.3 Liquidity
EYEN has a Current Ratio of 0.34. This is a bad value and indicates that EYEN is not financially healthy enough and could expect problems in meeting its short term obligations.
EYEN's Current ratio of 0.34 is on the low side compared to the rest of the industry. EYEN is outperformed by 94.85% of its industry peers.
EYEN has a Quick Ratio of 0.34. This is a bad value and indicates that EYEN is not financially healthy enough and could expect problems in meeting its short term obligations.
EYEN's Quick ratio of 0.34 is on the low side compared to the rest of the industry. EYEN is outperformed by 93.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.34 |
3. Growth
3.1 Past
EYEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.07%, which is quite impressive.
Looking at the last year, EYEN shows a very strong growth in Revenue. The Revenue has grown by 781.58%.
The Revenue for EYEN have been decreasing by -84.00% on average. This is quite bad
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.14%
Revenue 1Y (TTM)781.58%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%275%
3.2 Future
The Earnings Per Share is expected to grow by 15.19% on average over the next years. This is quite good.
EYEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 135.99% yearly.
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5Y15.19%
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5Y135.99%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
EYEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EYEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as EYEN's earnings are expected to grow with 20.36% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.63%
EPS Next 3Y20.36%
5. Dividend
5.1 Amount
EYEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.82
+5.26 (+49.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.67%
Inst Owner Change0%
Ins Owners0.74%
Ins Owner Change0.52%
Market Cap80.68M
Analysts47.5
Price Target163.2 (931.61%)
Short Float %3.99%
Short Ratio0.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.5%
Min EPS beat(2)5.64%
Max EPS beat(2)83.35%
EPS beat(4)3
Avg EPS beat(4)17.71%
Min EPS beat(4)-37.25%
Max EPS beat(4)83.35%
EPS beat(8)5
Avg EPS beat(8)6.62%
EPS beat(12)7
Avg EPS beat(12)7.27%
EPS beat(16)10
Avg EPS beat(16)16.18%
Revenue beat(2)0
Avg Revenue beat(2)-96.53%
Min Revenue beat(2)-96.75%
Max Revenue beat(2)-96.32%
Revenue beat(4)0
Avg Revenue beat(4)-97.36%
Min Revenue beat(4)-98.79%
Max Revenue beat(4)-96.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1204.21 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-34.16
EYN/A
EPS(NY)-26.52
Fwd EYN/A
FCF(TTM)-4.85
FCFYN/A
OCF(TTM)-4.84
OCFYN/A
SpS0.01
BVpS-1.9
TBVpS-1.9
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -708.22% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-514.41%
ROA(5y)-328.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.34 | ||
| Altman-Z | -62.11 |
F-Score3
WACC10.96%
ROIC/WACCN/A
Cap/Depr(3y)219.51%
Cap/Depr(5y)330.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.14%
EPS Next Y33.51%
EPS Next 2Y21.63%
EPS Next 3Y20.36%
EPS Next 5Y15.19%
Revenue 1Y (TTM)781.58%
Revenue growth 3Y-84%
Revenue growth 5YN/A
Sales Q2Q%275%
Revenue Next Year400.98%
Revenue Next 2Y356.17%
Revenue Next 3Y250.09%
Revenue Next 5Y135.99%
EBIT growth 1Y-0.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-88.59%
EBIT Next 3Y54.61%
EBIT Next 5Y39.01%
FCF growth 1Y2.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.27%
OCF growth 3YN/A
OCF growth 5YN/A